依达拉奉治疗急性脑出血的疗效分析

目的探讨依达拉奉对急性脑出血患者血清肿瘤坏死因子α(TNF-α)和白细胞介素-1(IL-1)水平的影响,并观察其治疗效果。方法将首次发病的急性脑出血患者90例,按病例对照研究方法随机分为对照组45例、治疗组45例,对照组是采用常规治疗,治疗组是在常规治疗基础上加用依达拉奉注射液30 mg+0.9%氯化钠注射液100 m L静脉滴注,2次/d,共14 d。比较两组患者于治疗前、后神经功能缺损程度(NIHSS)及日常生活活动量(ADL)评分,并进行疗效评定,检测患者血清TNF-α、IL-1水平的变化。结果治疗组在治疗后14 d NIHSS评分[(11.57±1.82)分]及ADL评分[(54.84±4.18)分]与对照组[(16.82±2.27)分、(45.13±3.93)分]相比,差异有统计学意义(均P0.05);治疗组临床疗效明显优于对照组(P0.05),其神经功能缺损程度明显改善,日常生活能力明显提高。治疗后,治疗组TNF-α[(13.06±2.90)ng/L]、IL-1[(4.31±2.23)ng/L]水平较对照组[(18.96±3.04)ng/L、(9.76±2.67)ng/L]比较,差异有统计学意义(均P0.05)。结论依达拉奉能减轻脑出血后炎性反应、清除自由基、改善神经功能缺损。

Effects of edaravone for treating acute intracerebral hemorrhage

Objective To explore the influence of edaravone for serum TNF-αand IL-1 and effects of in a-cute intracerebral hemorrhage.Mehtods Ninety cases with acute intracerebral hemorrhage were randomly divided into two groups:45 cases were treated with conventional therapy as control group,45 cases were treated with edaravone 30 mg and 0.9% NS 100 mL iv gtt,bid for 14 days as treatment group.The neurological impairment score (NIHSS)and activi-ty of daily living(ADL)scale were evaluated and compared before and after treatment between two groups.The changes of TNF -αand IL-1 were detected before and after treatment between two groups.Results The NIHSS and ADL of treatment group were higher than those of control group 14 days later(P <0.05).The clinical effect of treatment group was significantly better than control group (P <0.05).Both neurological impairment score and capability of daily living were improved obviously.Serum TNF-αand IL-1 in treatment group were significantly decreased compared with control group after treatment(P <0.05).Conclusion Edaravone can alleviate inflammatory reaction,eliminate free radicals, improve the symptoms of neurological impairment for acute intracerebral hemorrhage.